BR112016022439A2 - Composições farmacêuticas que compreendem cefepima ou sulbactama - Google Patents

Composições farmacêuticas que compreendem cefepima ou sulbactama

Info

Publication number
BR112016022439A2
BR112016022439A2 BR112016022439A BR112016022439A BR112016022439A2 BR 112016022439 A2 BR112016022439 A2 BR 112016022439A2 BR 112016022439 A BR112016022439 A BR 112016022439A BR 112016022439 A BR112016022439 A BR 112016022439A BR 112016022439 A2 BR112016022439 A2 BR 112016022439A2
Authority
BR
Brazil
Prior art keywords
sulbactam
pharmaceutical compositions
cefepim
pharmaceutically acceptable
acceptable derivative
Prior art date
Application number
BR112016022439A
Other languages
English (en)
Inventor
Bhagwat Sachin
Vithalbhai Patel Mahesh
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of BR112016022439A2 publication Critical patent/BR112016022439A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

COMPOSIÇÕES FARMACÊUTICAS QUE COMPREENDEM CEFEPIMA OU SULBACTAMA. A presente invenção refere-se a composições farmacêuticas que compreendem um composto beta-lactâmico selecionado dentre cefepima, sulbactama ou um derivado farmaceuticamente aceitável do mesmo, e um composto da fórmula (I) ou um estereoisômero ou um derivado farmacêutico aceitável do mesmo.
BR112016022439A 2014-03-29 2015-01-14 Composições farmacêuticas que compreendem cefepima ou sulbactama BR112016022439A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1194MU2014 IN2014MU01194A (pt) 2014-03-29 2015-01-14
PCT/IB2015/050268 WO2015150926A1 (en) 2014-03-29 2015-01-14 Pharmaceutical compositions comprising cefepime or sulbactam

Publications (1)

Publication Number Publication Date
BR112016022439A2 true BR112016022439A2 (pt) 2017-08-15

Family

ID=54239460

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022439A BR112016022439A2 (pt) 2014-03-29 2015-01-14 Composições farmacêuticas que compreendem cefepima ou sulbactama

Country Status (9)

Country Link
US (1) US20170151221A1 (pt)
EP (1) EP3125887A1 (pt)
JP (1) JP2017508769A (pt)
KR (1) KR20160130824A (pt)
CN (1) CN106900171A (pt)
BR (1) BR112016022439A2 (pt)
IN (1) IN2014MU01194A (pt)
MX (1) MX2016012646A (pt)
WO (1) WO2015150926A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230365561A1 (en) * 2020-09-01 2023-11-16 Ningxia Academy Of Agricul Ture And Forestry Sciences Beta-lactamase inhibitors and their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2397768C2 (ru) * 2004-12-02 2010-08-27 Венус Ремедиз Лимитед Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции
MX356373B (es) * 2011-05-28 2018-05-25 Wockhardt Ltd Composiciones que comprenden un agente antibacterial y tazobactam.
KR101738210B1 (ko) * 2011-07-26 2017-05-19 욱크하르트 리미티드 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
WO2013014496A1 (en) * 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

Also Published As

Publication number Publication date
JP2017508769A (ja) 2017-03-30
EP3125887A1 (en) 2017-02-08
MX2016012646A (es) 2016-10-28
CN106900171A (zh) 2017-06-27
WO2015150926A1 (en) 2015-10-08
US20170151221A1 (en) 2017-06-01
IN2014MU01194A (pt) 2015-10-02
KR20160130824A (ko) 2016-11-14

Similar Documents

Publication Publication Date Title
TW201613911A (en) Heterocyclic compounds and uses thereof
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
PH12016502255A1 (en) Combination
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
MX2017014035A (es) Formas solidas novedosas.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
BR112018074985A2 (pt) composições antibacterianas
NZ739518A (en) Compounds useful for inhibiting ror-gamma-t
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
IN2013MU03421A (pt)
BR112016022439A2 (pt) Composições farmacêuticas que compreendem cefepima ou sulbactama
IN2014MU00859A (pt)
IN2013MU03309A (pt)
IN2013MU03422A (pt)
IN2013MU03308A (pt)
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
JOP20190159B1 (ar) توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
MX2018010652A (es) Composiciones farmaceuticas.
BR112018006969A2 (pt) derivados de azetidina para formação de imagem de tau

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2549 DE 12-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]